Dr. Robert Figlin on the Increasingly Complicated Treatment Paradigm for Renal Cell Carcinoma

Robert Figlin, MD, FACP

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about the increasingly complicated treatment paradigm for renal cell carcinoma (RCC).

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC. He references a recent study published by The New England Journal of Medicine, where patients with advanced RCC had an improved overall survival rate of 5.4 months while on nivolumab versus everolimus.